

In the Claims

1-7 (canceled).

8 (previously presented). A composition for inhibiting a transcription factor in a cell, said composition comprising a double-stranded oligonucleotide, said oligonucleotide having a nucleotide sequence comprising the sequence TTCNNNGAA, wherein N represents any nucleotide, wherein said oligonucleotide comprises the sequence AGATTCTAGGAATTCAAATC (SEQ ID NO:1), and wherein said transcription factor binds to said oligonucleotide.

9 (previously presented). The composition according to claim 8, wherein said transcription factor is activated.

10 (previously presented). The composition according to claim 9, wherein said transcription factor is constitutively activated.

11 (previously presented). The composition according to claim 8, wherein the cell is a malignant cell.

12 (previously presented). The composition according to claim 8, wherein the cell is a leukemia cell.

13 (previously presented). The composition according to claim 8, wherein said transcription factor is STAT5.

14-18 (canceled).

20 (currently amended). An agent for inhibiting a transcription factor in a cell, comprising a double-stranded oligonucleotide, said oligonucleotide having a nucleotide sequence comprising the sequence TTCNNNGAA, wherein N represents any nucleotide, wherein said oligonucleotide

M:\Sherry\L\doc\ptu\Amn\USF-T176X.amd.adv-act.doc\DNB/sl

3

Docket No. USF-T176X
Serial No. 09/744,875

comprises the sequence AGATTCTAGGAATTCAAATC (SEQ ID NO:1) and a pharmaceutically acceptable carrier, diluent, or adjuvant.

21 (canceled).

22 (previously presented). The agent according to claim 20, wherein said transcription factor is STAT5.

23 (previously presented). The agent according to claim 20, wherein said transcription factor is activated.

24 (previously presented). The agent according to claim 23, wherein said transcription factor is constitutively activated.

25 (previously presented). The agent according to claim 20, wherein said cell is a malignant cell.

26 (previously presented). The agent according to claim 20, wherein said cell is a leukemia cell.

27 (previously presented). The agent according to claim 20, wherein said oligonucleotide comprises multiple copies of said nucleotide sequence TTCNNNGAA.

28 (previously presented). The agent according to claim 20, wherein said oligonucleotide comprises two copies of said nucleotide sequence TTCNNNGAA.

29 (previously presented). The agent according to claim 20, wherein said cell is a human cell.

30-36 (canceled).

M:\Sherry\I\doc\pto\Am\USF-T176X.am\adv-act.doc\DNB\sl

4

Docket No. USF-T176X
Serial No. 09/744,875

37 (previously presented). The composition according to claim 8, wherein said oligonucleotide comprises multiple copies of said nucleotide sequence TTCNNNGAA.

38 (previously presented). The composition according to claim 8, wherein said oligonucleotide comprises two copies of said nucleotide sequence TTCNNNGAA.

39 (previously presented). The composition according to claim 8, wherein said cell is a human cell.

40-63 (canceled).

64 (previously presented). The composition according to claim 8, wherein said oligonucleotide consists of the nucleotide sequence 5'-AGATTCTAGGAATTCAAATC-3' (SEQ ID NO: 1).

65 (previously presented). The agent according to claim 20, wherein said oligonucleotide consists of the nucleotide sequence 5'-AGATTCTAGGAATTCAAATC-3' (SEQ ID NO: 1).

66-77 (canceled).

M:\Sherry\1\loc\pt6\Amd\USF-T176X.amd.adv-act.doc\DNB/sl